A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT05123703 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

188

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing-Remitting Multiple Sclerosis

Interventions

DRUG: Ocrelizumab
OTHER: Ocrelizumab Placebo
DRUG: Fingolimod
OTHER: Fingolimod Placebo

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]